Question follow-through · 5670
Diethylstilbestrol: Side Effects
To ask the Secretary of State for Health and Social Care, what assessment he has made of the long-term health impacts associated with exposure to Diethylstilbestrol (DES).
About this written question
A written question asks a government minister for information in writing. Parliament publishes the question and any answer.
- Answering body
- Department of Health and Social Care
- Tabled
- 1 Jun 2026
- Target answer date
- 3 Jun 2026
- Answer
- 8 Jun 2026 · 7 calendar days after tabling
Elapsed calendar days describe the record timeline, not whether Parliament considers an answer on time.
Votes on this topic
- Terminally Ill Adults (End of Life) Bill: Second Reading · 11 Sept 2026
- Health Bill: Report Stage: Amendment 1 · 8 Sept 2026
- Health Bill: Report Stage: New Clause 143 · 8 Sept 2026
These Commons divisions share a topic label. The question did not necessarily lead to a vote.
Recorded timeline
1 Jun 2026
Question tabled
To ask the Secretary of State for Health and Social Care, what assessment he has made of the long-term health impacts associated with exposure to Diethylstilbestrol (DES).
3 Jun 2026
Target answer date
Date supplied by the official written-questions record.
8 Jun 2026
Answer published
Diethylstilbestrol (DES), also referred to as stilbestrol/stilboestrol, is an oestrogenic hormone formerly used in the treatment of threatened miscarriage and suppression of lactation. DES may still be prescribed in the United Kingdom for the treatment of...
Official data retrieved 28 Sept 2026.
Later records
Possible follow-up questions
Strong links require the same MP, department and exact heading. Other same-department questions are shown as unreviewed candidates, not as confirmed follow-ups. No debate link is asserted unless a stable source relationship exists.
No later same-department questions indexed.
This is an absence in covered public data, not evidence that no follow-up occurred elsewhere.